Oncology
Locally Advanced Head and Neck Cancer
0
Pipeline Programs↗
5
Active Trials↗
7
Companies Involved↗
Locally Advanced Head and Neck Cancer is an early-stage landscape with 0 programs across 7 companies. The most active players are Sanofi, Coastal Carolina Radiation Oncology, GSK.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
46
clinical trials
Completed26 · 57%
Terminated7 · 15%
Unknown status6 · 13%
Active, not recruiting3 · 7%
Recruiting2 · 4%
Withdrawn2 · 4%
Clinical Trials
Trial Activity
46 trials
Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer
Completed·—·Phase 2·NCT00176254·40 enrolled
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
Completed·—·Phase 2·NCT00544414·31 enrolled
Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer
Completed·—·Phase 2·NCT00176267·26 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)